Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid switching from levetiracetam to brivaracetam in pharmaco-resistant epilepsy in people with and without intellectual disabilities: a naturalistic case control study.
Watkins LV, Dunstall H, Musicha C, Lawthom C, John K, Bright C, Richings C, Harding K, Moon S, Pape SE, Winterhalder R, Allgar V, Thomas RH, McLean B, Laugharne R, Shankar R. Watkins LV, et al. Among authors: winterhalder r. J Neurol. 2023 Dec;270(12):5889-5902. doi: 10.1007/s00415-023-11959-w. Epub 2023 Aug 23. J Neurol. 2023. PMID: 37610448
Mortality risk in adults with intellectual disabilities and epilepsy: an England and Wales case-control study.
Sun JJ, Watkins L, Henley W, Laugharne R, Angus-Leppan H, Sawhney I, Shahidi MM, Purandare K, Eyeoyibo M, Scheepers M, Lines G, Winterhalder R, Perera B, Hyams B, Ashby S, Shankar R. Sun JJ, et al. Among authors: winterhalder r. J Neurol. 2023 Jul;270(7):3527-3536. doi: 10.1007/s00415-023-11701-6. Epub 2023 Apr 6. J Neurol. 2023. PMID: 37022478 Free PMC article.
Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study.
Sun JJ, Perera B, Henley W, Angus-Leppan H, Sawhney I, Watkins L, Purandare KN, Eyeoyibo M, Scheepers M, Lines G, Winterhalder R, Ashby S, De Silva R, Miller J, Philpott DE, Ashwin C, Howkins J, Slater H, Medhurst D, Shankar R. Sun JJ, et al. Among authors: winterhalder r. J Neurol. 2022 May;269(5):2750-2760. doi: 10.1007/s00415-021-10938-3. Epub 2022 Jan 24. J Neurol. 2022. PMID: 35067759
Correction to: Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study.
Sun JJ, Perera B, Henley W, Angus-Leppan H, Sawhney I, Watkins L, Purandare KN, Eyeoyibo M, Scheepers M, Lines G, Winterhalder R, Ashby S, De Silva R, Miller J, Philpott DE, Ashwin C, Howkins J, Slater H, Medhurst D, Shankar R. Sun JJ, et al. Among authors: winterhalder r. J Neurol. 2022 May;269(5):2761. doi: 10.1007/s00415-022-11012-2. J Neurol. 2022. PMID: 35247093 No abstract available.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
56 results